Deutsche Bank AG Raises Position in Stryker Co. (NYSE:SYK)

Deutsche Bank AG boosted its holdings in Stryker Co. (NYSE:SYK) by 8.0% during the fourth quarter, Holdings Channel.com reports. The fund owned 863,878 shares of the medical technology company’s stock after buying an additional 63,909 shares during the quarter. Deutsche Bank AG’s holdings in Stryker were worth $311,039,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Driehaus Capital Management LLC raised its position in Stryker by 16.2% during the fourth quarter. Driehaus Capital Management LLC now owns 1,911 shares of the medical technology company’s stock valued at $688,000 after purchasing an additional 267 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of Stryker by 4.1% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 106,586 shares of the medical technology company’s stock worth $38,376,000 after acquiring an additional 4,157 shares in the last quarter. Colonial Trust Co SC boosted its stake in shares of Stryker by 3.3% in the 4th quarter. Colonial Trust Co SC now owns 12,481 shares of the medical technology company’s stock valued at $4,494,000 after purchasing an additional 399 shares in the last quarter. CoreCap Advisors LLC lifted its stake in Stryker by 4.3% in the fourth quarter. CoreCap Advisors LLC now owns 9,889 shares of the medical technology company’s stock worth $3,561,000 after purchasing an additional 406 shares during the last quarter. Finally, Crestline Management LP bought a new stake in shares of Stryker in the 4th quarter valued at about $2,806,000. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on SYK shares. Royal Bank of Canada upped their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Citigroup restated a “buy” rating and set a $450.00 target price on shares of Stryker in a research note on Wednesday, February 26th. BTIG Research set a $403.00 price objective on shares of Stryker and gave the stock a “buy” rating in a research note on Monday, April 14th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $427.05.

Stryker Stock Performance

NYSE:SYK opened at $382.68 on Friday. The company has a fifty day moving average of $365.66 and a two-hundred day moving average of $374.20. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock has a market capitalization of $146.06 billion, a PE ratio of 49.31, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same period in the previous year, the business earned $2.50 EPS. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. As a group, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker’s payout ratio is currently 45.41%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.